Since CPT1A is the rate-limiting enzyme in fatty acid β-oxidation, deficiencies or aberrant regulation of this enzyme can lead to a variety of illnesses, including malignancies and metabolic disorders, making it a promising drug target for treatment87. This evidence concerns the gene CPT1A and metabolic disease.